Table 2.

Selection of characteristics of the infliximab market in the interviewed counties. Figures for quarter four of 2017

County	Tender with biosimilar	Biosimilar uptake (%)	Difference (%) in discounted price/DDD	Discounted price (SEK)/DDD cheapest product	Discounted price (SEK)/DDD infliximab
Skåne	Multi-winner (July 2015): Remsima® cheapest	92	− 47	60	64
Stockholm	Single winner (Jan 2017): Inflectra® cheapest	86	− 69	59	78
Västra Götaland	Multi-winner (Feb 2017): Inflectra® and Remicade® same price	47	1	59	59

Difference in discounted price/DDD: difference in discounted price per DDD of the biosimilar relative to the discounted price of the originator product in quarter four of 2017

DDD defined daily dose